NCT04696029 2026-03-02
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
Clinical Trials
6 trialsNCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT04301843 2026-02-03
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02679144 2026-01-21
NMTT
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02395666 2024-08-06
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
Phase 2 Completed